@_malia1999's tirzepatide journey, fact-checked

What did @_malia1999 actually say?

Honestly? Not much, medically speaking. The transcript is lyrics, not a health claim: "So now I say goodbye to the old me you're so fine, I can't wait wait wait wait wait wait to get your home." The actual content here is vibes, not information. She's documenting week one of tirzepatide use with the hashtag #peptidejourney and tagging it under peptide therapy content. The implicit message, even without spoken claims, is that tirzepatide is a transformation tool she's excited about. That framing does carry weight on a platform where 29,000 viewers are watching someone romanticize a prescription medication's first week.

To be fair, she didn't make a single factual health claim. She didn't promise weight loss numbers, didn't describe a mechanism, didn't tell anyone to try it. The fact-check concern here isn't what she said. It's what the video implies and what category it's been filed under, specifically peptide therapy, which tirzepatide is not.

Does the science back this up?

Tirzepatide has genuinely strong clinical data behind it, but it belongs in a different category than peptide therapy, and that distinction matters. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants with obesity lost up to 22.5% of body weight over 72 weeks on the highest dose. That's a real, peer-reviewed result.

But tirzepatide is a dual GIP and GLP-1 receptor agonist, a synthetic peptide analog developed as a pharmaceutical drug. It is not the same class of compound as BPC-157, TB-500, CJC-1295, or ipamorelin. Those are research peptides, most of which lack FDA approval and have limited or no human clinical trial data. Grouping tirzepatide into #peptidejourney content blurs that line in a way that could mislead viewers into thinking all peptides are similarly validated or similarly regulated. They are not.

Week one of tirzepatide typically involves dose titration and is associated with nausea, vomiting, and gastrointestinal side effects (Davies et al., 2021, The Lancet). The excitement in this video doesn't reflect that clinical reality.

What did they get wrong (or right)?

She didn't get anything factually wrong because she didn't say anything factual. But the categorical placement of this video under peptide therapy is misleading, and that's worth addressing directly. Tirzepatide (brand name Mounjaro or Zepbound) is an FDA-approved prescription medication. It is not a research peptide. Compounded versions of tirzepatide exist, but they are not equivalent to the FDA-approved brand-name product, and the FDA has flagged concerns about compounded tirzepatide quality and labeling.

The "goodbye to the old me" framing is emotionally potent and worth scrutinizing. First-week tirzepatide content that centers identity transformation skips the clinical reality: side effect management, medical supervision, contraindication screening, and the fact that discontinuation typically leads to weight regain (Wilding et al., 2022, Diabetes, Obesity and Metabolism). The drug works while you take it. That's not a reason not to use it, but it is information viewers deserve before they romanticize week one.

Credit where it's due: she didn't claim it cures anything, didn't give dosing advice, and didn't tell anyone else to start it.

What should you actually know?

If you're curious about tirzepatide, here's what the evidence actually shows. It's one of the most effective pharmacological weight loss tools studied to date, with the SURMOUNT program producing consistent results across multiple trials. It requires a prescription, medical evaluation, and ongoing supervision. It is not a peptide in the research peptide sense, and comparing it to BPC-157 or CJC-1295 in the same content bucket creates confusion about what's FDA-regulated and what isn't.

The first week is often the hardest, not the most exciting. Nausea affects a significant portion of new users. Dose escalation protocols exist for a reason. Anyone starting tirzepatide through a telehealth platform should be working with a licensed provider who has reviewed their full medical history, not making decisions based on transformation content from week one of someone else's journey.

• Tirzepatide is FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).
• Compounded tirzepatide is not the same as the brand-name drug.
• Research peptides like BPC-157 or ipamorelin have no comparable regulatory approval or clinical trial record.
• Week-one side effects are common and clinically expected, not a sign something is wrong.